Biotech Values

[rkrw]

dovp inlicensed a portfolio of products that were going to rot following a big pharma/big pharma merger. No discovery, all development. Great deal with mrk, adds a second major downside support beyond future indiplon royalties. ttp, ugghh. Got burned on iloperidone, no need to go back there